EXELIXIS INC (EXEL) Stock Fundamental Analysis

NASDAQ:EXEL • US30161Q1040

43.92 USD
+1.22 (+2.86%)
At close: Feb 13, 2026
44.5 USD
+0.58 (+1.32%)
After Hours: 2/13/2026, 8:05:51 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

Overall EXEL gets a fundamental rating of 6 out of 10. We evaluated EXEL against 522 industry peers in the Biotechnology industry. EXEL scores excellent points on both the profitability and health parts. This is a solid base for a good stock. EXEL scores decently on growth, while it is valued quite cheap. This could make an interesting combination. With these ratings, EXEL could be worth investigating further for value investing!.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year EXEL was profitable.
  • In the past year EXEL had a positive cash flow from operations.
  • Of the past 5 years EXEL 4 years were profitable.
  • Of the past 5 years EXEL 4 years had a positive operating cash flow.
EXEL Yearly Net Income VS EBIT VS OCF VS FCFEXEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 24.01%, EXEL belongs to the top of the industry, outperforming 97.51% of the companies in the same industry.
  • With an excellent Return On Equity value of 31.37%, EXEL belongs to the best of the industry, outperforming 97.51% of the companies in the same industry.
  • With an excellent Return On Invested Capital value of 26.31%, EXEL belongs to the best of the industry, outperforming 98.85% of the companies in the same industry.
  • EXEL had an Average Return On Invested Capital over the past 3 years of 10.78%. This is significantly below the industry average of 18.26%.
  • The 3 year average ROIC (10.78%) for EXEL is below the current ROIC(26.31%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 24.01%
ROE 31.37%
ROIC 26.31%
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
EXEL Yearly ROA, ROE, ROICEXEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

1.3 Margins

  • The Profit Margin of EXEL (29.63%) is better than 95.79% of its industry peers.
  • EXEL's Profit Margin has declined in the last couple of years.
  • EXEL has a Operating Margin of 35.85%. This is amongst the best in the industry. EXEL outperforms 97.70% of its industry peers.
  • EXEL's Operating Margin has declined in the last couple of years.
  • Looking at the Gross Margin, with a value of 96.63%, EXEL belongs to the top of the industry, outperforming 96.55% of the companies in the same industry.
  • EXEL's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 35.85%
PM (TTM) 29.63%
GM 96.63%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
EXEL Yearly Profit, Operating, Gross MarginsEXEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so EXEL is creating value.
  • EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
EXEL Yearly Shares OutstandingEXEL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
EXEL Yearly Total Debt VS Total AssetsEXEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

  • EXEL has an Altman-Z score of 12.81. This indicates that EXEL is financially healthy and has little risk of bankruptcy at the moment.
  • EXEL has a better Altman-Z score (12.81) than 84.87% of its industry peers.
  • There is no outstanding debt for EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 12.81
ROIC/WACC3.03
WACC8.68%
EXEL Yearly LT Debt VS Equity VS FCFEXEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.3 Liquidity

  • A Current Ratio of 3.75 indicates that EXEL has no problem at all paying its short term obligations.
  • EXEL's Current ratio of 3.75 is in line compared to the rest of the industry. EXEL outperforms 45.21% of its industry peers.
  • A Quick Ratio of 3.68 indicates that EXEL has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 3.68, EXEL is in line with its industry, outperforming 46.93% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.75
Quick Ratio 3.68
EXEL Yearly Current Assets VS Current LiabilitesEXEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • EXEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 49.73%, which is quite impressive.
  • The Earnings Per Share has been growing by 51.25% on average over the past years. This is a very strong growth
EPS 1Y (TTM)49.73%
EPS 3Y69.38%
EPS 5Y51.25%
EPS Q2Q%83.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%5.63%

3.2 Future

  • Based on estimates for the next years, EXEL will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.92% on average per year.
  • EXEL is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.52% yearly.
EPS Next Y17.33%
EPS Next 2Y21.2%
EPS Next 3Y19.22%
EPS Next 5Y15.92%
Revenue Next Year11.13%
Revenue Next 2Y12.7%
Revenue Next 3Y12.02%
Revenue Next 5Y7.52%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
EXEL Yearly Revenue VS EstimatesEXEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B
EXEL Yearly EPS VS EstimatesEXEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 15.86, which indicates a correct valuation of EXEL.
  • EXEL's Price/Earnings ratio is rather cheap when compared to the industry. EXEL is cheaper than 95.79% of the companies in the same industry.
  • EXEL's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.68.
  • The Price/Forward Earnings ratio is 13.51, which indicates a correct valuation of EXEL.
  • Based on the Price/Forward Earnings ratio, EXEL is valued cheaper than 96.55% of the companies in the same industry.
  • EXEL is valuated cheaply when we compare the Price/Forward Earnings ratio to 28.06, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 15.86
Fwd PE 13.51
EXEL Price Earnings VS Forward Price EarningsEXEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • EXEL's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. EXEL is cheaper than 96.55% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of EXEL indicates a rather cheap valuation: EXEL is cheaper than 97.13% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 15.1
EV/EBITDA 11.97
EXEL Per share dataEXEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

  • EXEL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of EXEL may justify a higher PE ratio.
  • A more expensive valuation may be justified as EXEL's earnings are expected to grow with 19.22% in the coming years.
PEG (NY)0.92
PEG (5Y)0.31
EPS Next 2Y21.2%
EPS Next 3Y19.22%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • EXEL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EXELIXIS INC

NASDAQ:EXEL (2/13/2026, 8:05:51 PM)

After market: 44.5 +0.58 (+1.32%)

43.92

+1.22 (+2.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-10
Earnings (Next)05-11
Inst Owners97.46%
Inst Owner Change-0.9%
Ins Owners2.18%
Ins Owner Change4.47%
Market Cap11.78B
Revenue(TTM)N/A
Net Income(TTM)677.90M
Analysts74.81
Price Target46.75 (6.44%)
Short Float %9.82%
Short Ratio10.04
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.63%
Min EPS beat(2)9.27%
Max EPS beat(2)13.99%
EPS beat(4)4
Avg EPS beat(4)20.73%
Min EPS beat(4)9.27%
Max EPS beat(4)49.01%
EPS beat(8)7
Avg EPS beat(8)31.52%
EPS beat(12)9
Avg EPS beat(12)17.76%
EPS beat(16)13
Avg EPS beat(16)41.2%
Revenue beat(2)0
Avg Revenue beat(2)-1.87%
Min Revenue beat(2)-3.02%
Max Revenue beat(2)-0.72%
Revenue beat(4)1
Avg Revenue beat(4)1.05%
Min Revenue beat(4)-3.02%
Max Revenue beat(4)9.31%
Revenue beat(8)3
Avg Revenue beat(8)4.36%
Revenue beat(12)4
Avg Revenue beat(12)2.52%
Revenue beat(16)7
Avg Revenue beat(16)3.42%
PT rev (1m)1.23%
PT rev (3m)4.42%
EPS NQ rev (1m)11.57%
EPS NQ rev (3m)28.55%
EPS NY rev (1m)1.7%
EPS NY rev (3m)13.74%
Revenue NQ rev (1m)-0.74%
Revenue NQ rev (3m)-0.96%
Revenue NY rev (1m)-0.25%
Revenue NY rev (3m)0.3%
Valuation
Industry RankSector Rank
PE 15.86
Fwd PE 13.51
P/S 5.15
P/FCF 15.1
P/OCF 14.89
P/B 5.45
P/tB 5.62
EV/EBITDA 11.97
EPS(TTM)2.77
EY6.31%
EPS(NY)3.25
Fwd EY7.4%
FCF(TTM)2.91
FCFY6.62%
OCF(TTM)2.95
OCFY6.72%
SpS8.53
BVpS8.06
TBVpS7.82
PEG (NY)0.92
PEG (5Y)0.31
Graham Number22.41
Profitability
Industry RankSector Rank
ROA 24.01%
ROE 31.37%
ROCE 33.48%
ROIC 26.31%
ROICexc 44.11%
ROICexgc 46.12%
OM 35.85%
PM (TTM) 29.63%
GM 96.63%
FCFM 34.08%
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
ROICexc(3y)19.16%
ROICexc(5y)19.43%
ROICexgc(3y)20.04%
ROICexgc(5y)20.66%
ROCE(3y)13.72%
ROCE(5y)11.89%
ROICexgc growth 3Y9.55%
ROICexgc growth 5Y2.44%
ROICexc growth 3Y10.88%
ROICexc growth 5Y3.03%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
F-Score8
Asset Turnover0.81
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 37.81%
Cap/Sales 0.49%
Interest Coverage 250
Cash Conversion 93.06%
Profit Quality 115.03%
Current Ratio 3.75
Quick Ratio 3.68
Altman-Z 12.81
F-Score8
WACC8.68%
ROIC/WACC3.03
Cap/Depr(3y)129.54%
Cap/Depr(5y)238.73%
Cap/Sales(3y)1.75%
Cap/Sales(5y)2.56%
Profit Quality(3y)151.16%
Profit Quality(5y)151.8%
High Growth Momentum
Growth
EPS 1Y (TTM)49.73%
EPS 3Y69.38%
EPS 5Y51.25%
EPS Q2Q%83.33%
EPS Next Y17.33%
EPS Next 2Y21.2%
EPS Next 3Y19.22%
EPS Next 5Y15.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%5.63%
Revenue Next Year11.13%
Revenue Next 2Y12.7%
Revenue Next 3Y12.02%
Revenue Next 5Y7.52%
EBIT growth 1Y34.85%
EBIT growth 3Y34.01%
EBIT growth 5Y13.3%
EBIT Next Year54.89%
EBIT Next 3Y25.82%
EBIT Next 5Y1.16%
FCF growth 1Y112.18%
FCF growth 3Y25.89%
FCF growth 5Y5.48%
OCF growth 1Y99.5%
OCF growth 3Y20.43%
OCF growth 5Y5.84%

EXELIXIS INC / EXEL FAQ

What is the fundamental rating for EXEL stock?

ChartMill assigns a fundamental rating of 6 / 10 to EXEL.


Can you provide the valuation status for EXELIXIS INC?

ChartMill assigns a valuation rating of 8 / 10 to EXELIXIS INC (EXEL). This can be considered as Undervalued.


Can you provide the profitability details for EXELIXIS INC?

EXELIXIS INC (EXEL) has a profitability rating of 7 / 10.


Can you provide the financial health for EXEL stock?

The financial health rating of EXELIXIS INC (EXEL) is 8 / 10.


What is the expected EPS growth for EXELIXIS INC (EXEL) stock?

The Earnings per Share (EPS) of EXELIXIS INC (EXEL) is expected to grow by 17.33% in the next year.